Annuity Payment Model For Cures May Get Test Drive In Massachusetts
First-ever implementation of often-discussed reimbursement approach for high-cost drugs would involve group of commercial payers to address “portability” issue and may start with Novartis’ Zolgensma.
You may also be interested in...
How Should Medicaid Pay For Cures? Sen. Grassley Likes Annuity Model
Finance Committee chairman wants a provision allowing Medicaid to make installment payments for high-cost curative treatments in drug pricing legislation. But Democrats worry such a model might encourage high prices.
Paying For Gene Therapy: Medicaid Will Be ‘Canary In Coal Mine’
Harvard Pilgrim's Michael Sherman and Cigna's Steve Miller advise gene therapy developers to consider the burden of high cost treatments on Medicaid programs when setting list prices.
Taking PBMs To The “OR”: Orphan Reinsurance Model Could Be New “Middleman” Role
MIT Center for Biomedical Innovation is proposing creation of Orphan Reinsurance Benefit Managers as one mechanism to help finance curative cellular and gene therapies. The idea may or may not prove viable – but it is a reminder that “middlemen” aren’t likely going away even if rebates do.